Equity Overview
Price & Market Data
Price: $9.17
Daily Change: -$0.0548 / 0.60%
Daily Range: $9.04 - $9.53
Market Cap: $1,494,990,720
Daily Volume: 3,416,598
Performance Metrics
1 Week: 9.26%
1 Month: -7.07%
3 Months: 40.03%
6 Months: 5.26%
1 Year: 16.16%
YTD: 36.90%
Company Details
Employees: 952
Sector: Health technology
Industry: Biotechnology
Country:
Details
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.